^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MIL62

    i
    Other names: MIL62, MIL 62, MIL-62
    Associations

    News

    Trials
    Company:
    Beijing Mabworks Biotech
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis (clinicaltrials.gov)
    P1/2, N=41, Active, not recruiting, Beijing Mabworks Biotech Co., Ltd.
    New P1/2 trial
    |
    MIL62
    6ms
    A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy (clinicaltrials.gov)
    P3, N=150, Active, not recruiting, Beijing Mabworks Biotech Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jan 2026
    Enrollment closed • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    MIL62
    6ms
    A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy (clinicaltrials.gov)
    P1/2, N=94, Completed, Beijing Mabworks Biotech Co., Ltd. | Recruiting --> Completed | Trial completion date: Oct 2025 --> Apr 2025
    Trial completion • Trial completion date
    |
    cyclophosphamide • MIL62
    6ms
    A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) (clinicaltrials.gov)
    P3, N=140, Active, not recruiting, Beijing Mabworks Biotech Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MIL62
    1year
    A Clinical Study of MIL62 in Primary Membranous Nephropathy (clinicaltrials.gov)
    P3, N=150, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    MIL62
    1year
    A Clinical Study of MIL62 in Primary Membranous Nephropathy (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Nov 2024 --> Mar 2025
    Trial primary completion date
    |
    cyclophosphamide • MIL62
    1year
    MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Phase classification: P1b/2 --> P1/2 | Trial primary completion date: May 2024 --> Jan 2024
    Phase classification • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • MIL62
    1year
    MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma (clinicaltrials.gov)
    P3, N=168, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • MIL62
    2years
    MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
    P1b/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial completion date: May 2023 --> May 2025 | Trial primary completion date: Jan 2023 --> May 2024
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • MIL62
    over2years
    MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma (clinicaltrials.gov)
    P3, N=168, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Mar 2023 --> Mar 2024
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • MIL62
    3years
    A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=43, Active, not recruiting, Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting --> Active, not recruiting | N=120 --> 43
    Enrollment closed • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Inokai (orelabrutinib) • MIL62
    over3years
    MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (clinicaltrials.gov)
    P1b/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Jun 2022 --> Jan 2023
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • MIL62